Yeah, that’s a good question and I think it’s the question that everyone is actually asking because we have seen data in KIM-1 levels in adjuvant clear cell. We have seen some data in advanced clear cell until now. I don’t think there is any published data in non-clear cell renal cancer. I think probably the future will tell because there are a lot of controversies around KIM-1 because we have not been able to establish a cutoff...
Yeah, that’s a good question and I think it’s the question that everyone is actually asking because we have seen data in KIM-1 levels in adjuvant clear cell. We have seen some data in advanced clear cell until now. I don’t think there is any published data in non-clear cell renal cancer. I think probably the future will tell because there are a lot of controversies around KIM-1 because we have not been able to establish a cutoff. For example, the data is too noisy. Even in our samples, we have some outliers and we cannot really explain why that happened. So probably the future will tell and we will need to take all of this into consideration before incorporating KIM-1 in prospective validating trials, which would be the first step. And because the assays that have been used are different, the levels have been different I think it might be challenging – it’s what we are hoping that in the future, in the not so distant future, we might be able to incorporate it into our daily practice but I think it’s going to be challenging and we still need to look at KIM-1 as a possible biomarker but we need more data so yeah it’s the same as ctDNA in kidney cancer as well so we hope and we have shown also some correlation between ctDNA and KIM-1 – it was only in 12 patients but we have seen a correlation but there is not much data until now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
